Country: Philippines
Language: English
Source: FDA (Food And Drug Administration)
Insulin Human (rDNA)
Getz Pharma (Phils.), Inc.
Insulin Human (rDNA)
100 IU/mL
Suspension for Injection (IM/IV/SC)
Glass vial with yellow flip-off cap x 10 mL (Box of l's), Glass vial x 10mL (Box of 1's)
Getz Pharma Pvt. Ltd., Pakistan
Anti-Diabetic
For the treatment of Diabetes Mellitus type I; Diabetes Mellitus type II either alone or in combination with oral anti-diabetic agents; emergency management of Diabetic ketoacidosis; adult patients with diabetes mellitus for the control of hyperglycemia should be used in regimens that include a longer-acting insulin.
2020-10-22
Injection sites should be rotated within an anatomic region in order to avoid lipodystrophy. An injection should be followed within 30 minutes by a meal or a snack containing carbohydrates. ADMINISTRATION 1. Pinch the skin between two fingers, push the needle into the skinfold and inject the insulin under the skin. 2. Keep the needle under the skin for at least 6 seconds to make sure all the insulin has been injected. 3. If blood appears after the needle has been withdrawn, press the injection site lightly with a finger. _Do not reuse needles. Dispose of the needle in a responsible manner._ _Needles must not be shared._ ADVERSE EFFECTS Hypoglycemia is the most frequently occurring undesirable effect of insulin therapy that a patient with diabetes may suffer. Symptoms of hypoglycemia usually occur suddenly. They may include cold sweat, cool pale skin, nervousness or tremor, anxious feeling, unusual tiredness or weakness, confusion, difficulty in concentration, headache, nausea and palpitation. Severe hypogl ycemia may lead to unconsciousness and may result in temporary or permanent impairment of brain function or even death. Weight gain is common when taking insulin. Edema and refraction anomalies may occur upon ‘initiation’ of insulin therapy. Local hypersensitivity reactions (redness, swelling and itching at the injection site) are those transitory reactions, which may occur during the treatment with insulin and normally disappear during continued treatment. Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection site within an area. Generalised hypersensitivity reactions may occur occasionally and can cause generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic edema, difficulties in breathing, palpitation and reduction in blood pressure. These are potentially life threatening. CONTRAINDICATIONS Insulin is contraindicated in: − Patients with hypersensit ivity to any components of this medication. − Patients with hypoglycemia. − Patients in Read the complete document